Koninklijke Philips N.V.

OTCPK:RYLP.F Stock Report

Market Cap: US$23.6b

Koninklijke Philips Valuation

Is RYLP.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RYLP.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RYLP.F ($24.62) is trading below our estimate of fair value ($58.06)

Significantly Below Fair Value: RYLP.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RYLP.F?

Key metric: As RYLP.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RYLP.F. This is calculated by dividing RYLP.F's market cap by their current revenue.
What is RYLP.F's PS Ratio?
PS Ratio1.3x
Sales€18.04b
Market Cap€22.58b

Price to Sales Ratio vs Peers

How does RYLP.F's PS Ratio compare to its peers?

The above table shows the PS ratio for RYLP.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.3x
ZBH Zimmer Biomet Holdings
2.8x4.3%US$21.3b
STE STERIS
3.8x6.0%US$20.5b
IDXX IDEXX Laboratories
8.8x7.8%US$33.8b
GEHC GE HealthCare Technologies
1.8x4.2%US$36.1b
RYLP.F Koninklijke Philips
1.3x4.8%US$22.6b

Price-To-Sales vs Peers: RYLP.F is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (4.3x).

Price to Sales Ratio vs Industry

How does RYLP.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

49 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.6x4.4%US$201.98m
ARAY Accuray
0.4x5.5%US$186.05m
NVRO Nevro
0.3x2.8%US$142.02m
RMTI Rockwell Medical
0.7x-7.3%US$67.22m
RYLP.F 1.3xIndustry Avg. 3.2xNo. of Companies49PS02.85.68.411.214+
49 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: RYLP.F is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is RYLP.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RYLP.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RYLP.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RYLP.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$24.62
US$29.84
+21.2%
15.7%US$41.47US$23.85n/a17
Dec ’25US$27.22
US$30.14
+10.7%
15.8%US$41.98US$24.14n/a17
Nov ’25US$25.58
US$31.04
+21.3%
15.7%US$43.35US$24.92n/a17
Oct ’25n/a
US$30.84
0%
13.6%US$38.74US$25.46n/a17
Sep ’25US$29.84
US$30.70
+2.9%
13.4%US$38.90US$24.72n/a17
Aug ’25n/a
US$28.85
0%
13.7%US$37.90US$21.98n/a17
Jul ’25US$25.53
US$27.00
+5.7%
15.1%US$35.30US$20.77n/a17
Jun ’25US$27.60
US$27.24
-1.3%
15.3%US$35.71US$21.00n/a17
May ’25US$26.72
US$24.79
-7.2%
18.3%US$35.09US$18.06n/a17
Apr ’25US$20.44
US$21.28
+4.1%
17.0%US$30.39US$16.77n/a17
Mar ’25US$20.17
US$21.48
+6.5%
16.7%US$30.25US$16.69n/a18
Feb ’25US$21.35
US$21.79
+2.1%
16.5%US$30.48US$16.82n/a18
Jan ’25US$23.25
US$21.45
-7.7%
18.6%US$30.85US$15.96n/a18
Dec ’24US$19.97
US$20.76
+4.0%
21.3%US$30.52US$14.42US$27.2218
Nov ’24US$19.20
US$19.70
+2.6%
23.5%US$29.61US$11.64US$25.5818
Oct ’24US$20.04
US$20.06
+0.1%
24.8%US$30.64US$11.15n/a17
Sep ’24US$22.37
US$20.84
-6.9%
24.3%US$31.92US$11.61US$29.8417
Aug ’24US$20.87
US$20.88
+0.04%
24.8%US$32.18US$11.71n/a17
Jul ’24US$21.10
US$19.17
-9.2%
25.0%US$31.66US$11.52US$25.5316
Jun ’24US$18.89
US$18.45
-2.3%
25.9%US$31.12US$11.32US$27.6016
May ’24US$21.21
US$18.02
-15.0%
27.4%US$30.64US$9.89US$26.7217
Apr ’24US$16.08
US$15.45
-3.9%
32.7%US$29.30US$8.79US$20.4417
Mar ’24US$16.74
US$15.58
-6.9%
33.8%US$29.70US$8.91US$20.1716
Feb ’24US$17.90
US$16.01
-10.6%
33.4%US$30.50US$9.15US$21.3516
Jan ’24US$14.91
US$15.42
+3.4%
33.2%US$29.25US$9.44US$23.2516
Dec ’23US$14.97
US$15.20
+1.5%
34.1%US$28.67US$9.25US$19.9715

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 21:18
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Koninklijke Philips N.V. is covered by 54 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wim GilleABN AMRO Bank N.V.
Sumit SayalAlphaValue
Fabrizio SpagnaAxia Financial Research